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CASE PRESENTATION
A 37-year-old male was referred in 1999 for evaluation of
proteinuria and a serum creatinine of 1.8 mg1. He was
asymptomatic. Apart from hyperlipidemia, there was no
history of diabetes, hypertension, macroscopic hematuria,
or family history of renal disease or any inheritable
disorder. On evaluation the patient was in good heath and
a review of systems was unremarkable. His weight was
70 kg, blood pressure was 115/75 mm Hg, pulse rate was
78, and temperature was 361C. The physical examination
was remarkable because of two reddish angiectasias of
about 3 mm of diameter in the trunk, which blanched
under pressure and was compatible with the diagnosis of
angiokeratomas. Urinalysis showed a pH of 5.4, osmolality
478 mosm kg1, protein 116 mg dl1, negative ketones,
and normal microscopic findings. Twenty-four-hour urine
collection showed protein excretion of 2.4 g, with a
creatinine clearance of 41 ml 17:41 ml min1 1.73 m2.
Serum and urine protein electrophoresis were negative
for a monoclonal protein. His serum albumin level
was normal at 4 g dl1. Other test results were normal
or negative, including complement, antineutrophil
cytoplasmic antibody, anti-DNA antibody, and hepatitis
serology results. Renal ultrasound showed normal size
kidneys, bilaterally. To ascertain the cause of his
proteinuria, a renal biopsy was performed.
RENAL BIOPSY FINDINGS
Light-microscopy examination showed focal and segmental
glomerulosclerosis (5/10 glomeruli totally sclerosed), as well
as patchy interstitial fibrosis and tubular atrophy. Glomerular
visceral epithelial cells showed cytoplasmic vacuolization,
which was also present focally within tubular epithelial cells.
No immune deposits were detected by immunofluorescence
microscopy. Electron microscopy showed laminated myelin
figures (zebra bodies) in glomerular visceral epithelial cells,
and no immune deposits were identified. Leukocyte levels
of a-galactosidase (a-Gal) were significantly reduced at 5.4%,
establishing the diagnosis of Fabry disease.
GENETIC AND MOLECULAR ANALYSIS
Because of his unique presentation, genetic diagnosis was
performed by using polymerase chain reaction sequencing.1
We identified a complex mutation (insertion and deletion)
A368gsX24 (1102delGinsTTATAC), which has been pre-
viously described.1 After his diagnosis, screening for Fabry
disease was offered to his only child. The father’s parents were
deceased at the time of diagnosis. His 17-year-old daughter
was found to have the same mutation, but leukocyte a-Gal
levels were 50% of normal.
CLINICAL FOLLOW-UP
Cardiac echocardiogram showed no evidence of left ventri-
cular hypertrophy. Cranial magnetic resonance imaging
disclosed two small areas suggestive of ischemic stroke. Slit-
lamp examination of the eyes disclosed cornea verticillata.
He was treated initially with angiotensin-converting inhibitor
(enalapril 5 mg b.i.d.). Attempts to increase the dose further
resulted in the development of symptomatic hypotension.
Proteinuria persisted and he was started on enzyme replace-
ment therapy (ERT) with agalsidase-beta (1 mg kg1 every
2 weeks). Despite combined angiotensin-converting inhibitor
and ERT, proteinuria (Figure 1) and renal disease progressed,
with the patient reaching end-stage renal disease (ESRD)
three and a half years after starting ERT (Figure 2). He never
developed symptomatic peripheral neuropathy, vertigo, or
lymphedema, and apart from angiotensin-converting inhi-
bitor therapy he was on no other medication until late into
the progression of his renal failure when erythropoietin and
phosphate binder treatment was started.
DISCUSSION
Fabry disease was first described in 1898 by Johaness Fabry
and William Anderson, two physicians working independently
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of each other, in Bonn and London, respectively. They
described patients with ‘angiokeratoma corporis diffusum’,
the red-purple maculopapular skin lesions characteristic
of the disorder (Figure 3). After these initial cases, other
associated symptoms were described and eventually the
lysosome was identified as the key organelle responsible for
the pathology of the disease. We now know that the disease is
due to an X-linked recessive inborn error of glycosphingo-
lipid metabolism caused by the deficient activity of the
lysosomal enzyme, a-Gal A.2 The enzymatic defect results in
the progressive accumulation of neutral glycosphingolipids,
(predominately globotriaosylceramide, GL-3), particularly
in the vascular endothelial cells of the kidney and heart.
A limited number of studies have investigated the incidence
of lysosomal storage diseases (defined as the total number
of cases diagnosed within a certain period of time, divided by
the total number of live births in the same period). For Fabry
disease, the incidence/prevalence oscillates from 1 in 40 000
to 1:117 000 in United States and Australia to 1:833 000 in
Northern Portugal, the majority of them being Caucasians.3,4
These figures are likely to underestimate the real prevalence
of the disease as many patients with Fabry disease go
undiagnosed due to the complexity of the diagnosis. Affected
males have little, if any, a-Gal A activity, and the depo-
sition of GL-3 occurs primarily in the lysosomes of vascular
endothelial cells as well as in epithelial and smooth muscle
cells throughout the body. Early clinical manifestations
of the disease include angiokeratoma, acroparesthesias,
episodic pain ‘crises’, hypohydrosis, and gastrointestinal
complains. With time, progressive GL-3 accumulation in
the microvasculature leads to renal, cardiovascular, and
cerebrovascular manifestations such as proteinuria, renal
failure, cardiac arrhythmias, and strokes leading to early
death during the fourth and fifth decade of life, in affected
men4 (Table 1).
Renal manifestations of Fabry disease are more evident
in hemizygous males than in heterozygous females. However,
due to non-random X inactivation, some females have
a significant burden of disease, including renal failure.
On gross description, the kidney may be enlarged due to
accumulation of storage material. In some cases, cortical or
parapelvic cysts have been demonstrated by radiographic
imaging. On light microscopy, the glomerular tuft shows
vacuolated glomerular cells, especially podocytes (Figure 4).
Similar changes are present in the endothelial and mesangial
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Figure 1 | Proteinuria (g 24 h1) before and after start of ERT.
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Figure 2 | Serum creatinine values before and after start of ERT.
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Figure 3 | Angiokeratomas: the red-purple maculopapular skin lesions characteristic of the disorder. (a) Skin lesions on buttocks, and
(b) lesions on the umbilicus (provided by Dr Mark R Pittelkow, Department of Dermatology, Mayo Clinic, Rochester, MN).
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cells, and in parietal epithelial cells of the Bowman’s capsule.
The vacuolated appearance is due to removal of the
glycolipids during clearing and paraffin embedding of the
tissue, but can be easily demonstrated in semithin sections of
tissue embedded in epoxy resin and stained with toluidine
blue (Figure 5). Similar cytoplasmic vacuolation can also be
seen in the renal tubules, particularly in the epithelium of
Henle’s loop and the distal tubule. Cytoplasmic vacuolization
can also be seen in endothelial cells of small arteries and
arterioles, smooth muscle cells, and in interstitial cells,
producing an early concentrating defect.5 Later, progressive
glomerulosclerosis manifested by proteinuria and ischemic
changes in renal microvasculature result in capillary wall
thickening, tubular atrophy, interstitial fibrosis, and arterial
and arteriolar sclerosis. Immunofluorescence is negative.
Electron microscopy shows enlarged podocytes filled with
osmiophilic, granular to lamellated membrane structures
(zebra bodies) (Figure 6). Accumulation of GL-3 leads to
microvascular obstruction and ischemia, and ultimately renal
function deteriorates with ESRD developing in the third to
fifth decades of life, although cases of ESRD developing in the
second decade have been reported.6
The case reported hereby is a patient who presented with
proteinuria with no other symptoms. A renal biopsy and
genetic analysis disclosed that the patient was affected by
Fabry disease with preferential kidney involvement. Fabry
disease presenting solely with renal involvement is rare, and
only a few cases have been reported in the literature.7–9 Nakao
et al.7 screened 514 unselected Japanese male patients with
ESRD treated with chronic hemodialysis patients and
identified six patients with Fabry disease (occurrence rate
1.2%). Among the cases reported by Nakao and co-workers,
one had classic Fabry disease that was misdiagnosed, four had
left ventricular hypertrophy, and only one had a normal
echocardiogram. It appears that the kidney and heart are
frequently involved in non-classic Fabry disease and that
there are overlapping symptoms between cardiac and renal
variants.10,11 These data show that undiagnosed Fabry
patients on dialysis may account from 0.25 to 1.2% of the
total amount of male patients on dialysis.
Until now, all reported cases of the renal variant, including
those reported by Nakao and co-workers above, are caused by
missense mutations, while patients with the classical
phenotype have nonsense, severe missense, frameshift, and
splicing mutations that result in no enzyme protein or
Table 1 | Potential disease manifestations by average age
of onset
Childhood
Episodic pain crises, acroparesthesia
Hypohidrosis
Corneal and lenticular opacities
Recurrent fever
Heat and cold intolerance
Adolescence
Angiokeratomas
Fatigue
Adulthood
Renal dysfunction
Isosthenuria, proteinuria, progressive renal insufficiency
Cerebrovascular/neurological complications
Early stroke, diplopia, dysarthria, nystagmus, nausea, vomiting, ataxia,
vertigo, dizziness, hearing loss and tinnitus
Cardiac dysfunction
Left ventricular hypertrophy, coronary artery disease, arrhythmias,
mitral insufficiency, congestive heart failure
Other signs/symptoms
Cornea verticillata, tortuous retinal vessels
Growth retardation, delay puberty
Impaired fertility
Episodic diarrhea, weight loss
Changes in joints and bones
Impaired social functioning
Depression
Decreased quality of life
Figure 4 | Glomerulus showing vacuolated podocytes (arrows)
(hematoxylin and eosin,  400).
Figure 5 | Glomerulus showing enlarged podocytes containing
cytoplasmic lamellated inclusion bodies (arrows) (toluidine blue,
 600).
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mutant enzymes with very low activity. The case reported
herein is produced by a frameshift mutation, with the
most outstanding fact being that such a severe mutation
(1102delG/insTTATAC) gives rise to a ‘renal variant’ of Fabry
disease.
Attempting to correlate the genotype to phenotypic
variations is not straightforward. Many heterozygous and
some hemizygous patients show no symptoms of the disease
during most of their life. Residual a-Gal A activity as well as
other genetic factors may affect the phenotype. Modifying
genes may include those involved in glycolipid metabolism,
which may increase a-Gal substrates, thus altering the disease
severity. Also, differences in intracellular factors in different
cell, tissues and organs may affect the transcription rate of the
a-Gal gene, which may explain why the same kind of
mutation accounts for such different phenotypes. The patient
reported here shows mostly renal involvement (cornea
verticillata and two small angiokeratomas were the only
extra-renal feature), with the diagnosis made by renal biopsy.
Why having some degree of a-Gal activity can protect one
organ but not the other remains to be explained. In female
patients, a non-random X-inactivation limited to the kidney
(skewed towards inactivation of the wild type allele) could be
the reason for the outstanding phenotype.
In addition to the classical Fabry disease phenotype,
and to the ‘renal’ variant, a ‘cardiac’ variant has also been
identified.11,12 These patients have residual a-Gal A activity,
with GL-3 deposition confined to myocytes, and do not
manifest the whole spectrum of symptoms present in
classical Fabry disease.12 Clinical presentation is usually in
the fifth to the eighth decade with left ventricular
hypertrophy, mitral insufficiency, and cardiomyopathy.
Later in life, however, many of these patients will manifest
renal involvement characterized by proteinuria without
progression to ESRD.11,12 Interestingly, the case reported by
Sawada et al.9 of a ‘renal variant’ showed the same mutation
(G to A transition) as the patient reported by Sakuraba
et al.13 who had a cardiac variant, reinforcing the impression
of idiosyncratic transcriptional rate in different organs.
Although it seems reasonable to use the terms ‘renal and
cardiac variants’ to describe these cases, we believe that the
term ‘extreme phenotypes’ would be more precise to explain
the existence of such different phenotypes. In fact, most of
the reported patients with the ‘renal variant’ have some kind
of systemic involvement, such as cornea verticillata, left
ventricular hypertrophy, or neurological involvement. In
all cases the involvement of other organs was minor in
relation to the kidney. However, it is very important to
know these cases exist in order not to miss the diagnosis in
these patients.
Since Fabry disease is a potentially treatable condition, it is
imperative to consider it in the differential diagnosis of any
patient presenting with chronic progressive renal failure and
proteinuria that cannot be readily explained by history or
routine laboratory evaluation. This is of special importance
in cases where there is unexplained family history of renal
disease. The determination of a-Gal activity is easy and the
renal biopsy shows typical changes, as described above.
Screening for Fabry disease may be carried out by determin-
ing a-Gal levels in males with suggestive clinical features and/
or compatible renal biopsy findings. The a-Gal A activity
can easily be measured in plasma and leukocytes using the
4-methylumbelliferyl-a-D-galactopyranoside method.14 There
are fewer pitfalls in the leukocyte assay than in the plasma
assay. Classically affected hemizygotes have very low or
undetectable enzyme activity, but some hemizygotes may
have higher residual activity in plasma and/or leukocytes. It is
therefore important to confirm the mutation in these
individuals. The a-Gal A activity in females can range from
the low level found in affected males to the normal range,
possibly due to skewed X-inactivation. Therefore, hetero-
zygotes cannot be reliably defined by enzymatic analysis,
and mutation detection is mandatory if Fabry disease is
suspected. The GLA gene, located at Xq22.1, is 12 kb in length
and contains seven exons. To date, close to 400 mutations
have been described in the GLA gene, most of which are
private missense or nonsense mutations.15 Therefore, the
whole gene must be sequenced when looking for mutation in
the GLA gene.
Enzyme replacement therapy
Until recently, recognition of Fabry disease did not impact on
the patient’s prognosis, since no treatment was available.
However, the availability of ERT with recombinant a-Gal has
offered the promise of altering the natural history of this rare
form proteinuric renal disease.16 Currently, there are two
forms of ERT available for the treatment of Fabry disease:
(1) Replagal (agalsidase-alpha; Shire Human Genetic Therapies
Inc., Cambridge, MA, USA) and (2) Fabrazyme (agalsidase-
beta; Genzyme Corporation Inc., Cambridge, MA, USA).
With the exception of the structures of the oligosaccharide
Figure 6 | Electron micrograph showing electron-dense laminated
myelin figures in glomerular epithelial cells ( 5000).
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side chains, the primary amino-acid sequences of the gene
products are the same.17 The approved doses of agalsidase-
alpha and agalsidase-beta are 0.2 and 1.0 mg kg1, intra-
venously, biweekly, respectively. In the US, only agalsidase-beta
has been approved for the treatment of Fabry disease by the
Food and Drug Administration, although both agents are
available for clinical use in other countries.18
Randomized, placebo-controlled trials, and long-term,
open-label extension studies of both products have consis-
tently demonstrated that ERT reduces GL-3 levels in plasma
and urine as well as glycosphingolipids accumulation in
capillary endothelial cells, renal glomerular cells, and tubular
epithelial cells.19,20 In patients with relatively mild disease,
the use of ERT has been able to decrease neuropathic pain,
stabilize renal function, decrease left ventricular mass, and
relieve gastrointestinal symptoms.20,21 However, strokes
continue to occur in some patients despite ERT.21 Similarly,
the coronary microvascular dysfunction appears not to be
completely reversed by ERT.22
Results of a multicenter phase IV trial in which 82 patients
with initial glomerular filtration rate (GFR) values
o80 ml min1 1.73 m2 who were prospectively randomized
(2:1) to treatment with agalsidase-beta or placebo have
recently been published.23 The median time in treatment was
18.5 months and the study ended when approximately one-
third of the patients had experienced a total of 27 clinical
events (renal, cardiac, and cerebrovascular complications or
death), 17 (63%) of which were renal events. Clinical events
occurred less in the agalsidase-beta group, but the differences
were not statistically significant. There was, however, an
imbalance in the degree of baseline proteinuria, with patients
allocated to the ERT arm having significantly higher degrees
of proteinuria than those on the placebo arm, a fact that
complicates the interpretation of the outcome of the study.24
After adjustment for baseline proteinuria, the intention-
to-treat analysis showed that ERT was associated with a 53%
risk reduction of an event, although due to the small number
of patients in the trial, the results were still not statistically
significant (P¼ 0.058). When the analysis was limited to
the 74 patients who had no protocol violation, the 61%
reduction in risk for a clinical event with ERT was statistically
significant (P¼ 0.034). Secondary analysis of this study
showed that the benefit of ERT was greater in those patients
with GFR values 455 ml min1 per 1.73 m2, but those
patients with more severe renal disease did not exhibit the
same benefits.23 In this study, 12% of the patients were
affected women, but the authors do not report on the
outcomes on these patients. Most treatment-related events
were mild or moderate infusion-associated reactions (rigors
and fever), occurred in 55% of patients in the agalsidase-beta
group and 23% of patients in the placebo group, and were
most common during the first 6 months of treatment.
One patient in the agalsidase-beta group experienced severe
hypotension and had a positive serum IgE test result. Two
others who had developed urticaria and rigors during
infusions subsequently developed a positive skin test. Both
were subsequently re-challenged and continue to receive
treatment without anaphylaxis. Forty-three patients (68%)
developed IgG antibodies against recombinant agalsidase-
beta.23 These antibodies tended to fall over time and do not
appear to affect therapeutic efficacy.21 Data collected from a
European post-marketing follow-up survey has confirmed
that ERT is safe and well tolerated in adults and children
when used in a wide range of patients and in daily clinical
practice, including home therapy.
Proteinuria has emerged as a major player in the develop-
ment of progressive tubular injury, interstitial fibrosis, and
GFR loss, including Fabry disease.21 The higher the sustained
levels of proteinuria, the faster the decline in renal function.
Two studies that underscore the importance of proteinuria in
Fabry patients as well as the limitations of EFR in addressing
this issue have recently been published.16 Germain et al.25
provide the data on 58 patients who completed a 20-week,
double-blind, randomized, placebo-controlled, phase III
study of agalsidase-beta, and were transitioned to an exten-
sion trial to receive biweekly 1 mg kg1 agalsidase-beta for up
to an additional 54 months. Median serum creatinine and
estimated glomerular filtration rate (eGFR) remained normal
in the 41 patients with renal data at month 54. Six patients
had renal disease progression; most (four of six) were older
than 40 years and had significant proteinuria at baseline and
evidence of sclerotic glomeruli pretreatment.25 In the second
study, Schiffmann et al.26 evaluated whether adult male
patients with Fabry disease who had demonstrated a
continuing decline in GFR despite 2–4 years of conventionally
dosed agalsidase-alpha therapy (0.2 mg kg1 biweekly) would
benefit from increasing ERT to a weekly dosing. Before
switching to weekly dosing, the 11 patients who participated
in the study had a mean rate of change in eGFR of 8.0±
0.8 ml min1 1.73 m2 per year. After switching to weekly
dosing, three patients demonstrated an improvement in
eGFR and six patients demonstrated a slowing in the rate of
eGFR decline; only two patients failed to improve their eGFR
slope.26 Although derived from a limited number of patients,
these data suggest a possible dose-dependent effect of ERT. It
should be noted, however, that the dosing interval used by
the authors is not approved in any country where agalsidase-
alpha is approved for the treatment of Fabry disease. What
will be the impact of increased ERT dosing/frequency on this
already very expensive therapy (B$250 000 per year for the
average adult)?
ERT in patients with end stage renal disease
The detection of Fabry patients among those receiving renal
replacement therapy is also important for other organs apart
from the kidney might be involved, and treatment with ERT
may ameliorate symptoms or prevent further progression
of cardiovascular and cerebrovascular complications. Adminis-
tration of agalsidase-alpha during hemodialysis is not
associated with a reduction of enzyme activity or enzyme loss
into the dialysate.27 A recent study showed that in Fabry
disease patients undergoing dialysis, ERT is associated with
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improvement in symptoms and slower progression of left
ventricular hypertrophy.28
ERT in kidney transplant patients
Similarly, kidney transplantation can successfully correct
the renal failure in patients with ESRD secondary to Fabry
disease.29 However, as in patients on dialysis, other aspects of
Fabry disease persist and progress. Indeed, late cardiovascular
and cerebrovascular complications comprise the main
cause of the high morbidity and mortality in Fabry patients
receiving a kidney transplant.29 Preliminary data in small
number of patients suggest that ERT is safe and often
effective against extra-renal manifestations in kidney trans-
plant patients with Fabry disease.
Angiotensin II blockade
In both diabetic and non-diabetic nephropathy patients,
angiotensin-converting enzyme inhibitors and/or angiotensin
II receptor blockers are cardioprotective, reduce proteinuria,
and slow progression of renal disease. The degree of
protection is related to the degree of proteinuria reduction
and if proteinuria is not lowered, the benefit is substantially
attenuated. Data from the RENAAL study show that the renal
protective effect of angiotensin II blockade was nearly fully
explained by its antiproteinuric effect.30 In patients with
Fabry disease, proteinuria degree at the time of initiation of
ERT can predict the rate of decline of GFR. ERT alone will
not reduce overt proteinuria in Fabry disease, but blockade of
the angiotensin II system has been shown to reduce
proteinuria and to stabilize GFR.31 It is important to keep
in mind, as illustrated by the present case, that blood pressure
is not typically elevated in patients with Fabry disease.21,23,25,26
Thus, careful titration of these agents is needed, with the
target being reduction of proteinuria rather than in systemic
blood pressure. An ongoing prospective study in 40 Fabry
patients with significant renal involvement undergoing
ERT addresses the safety and efficacy of angiotensin II block-
ade in these patients. (http://www.clinicaltrials.gov/ct/search;
jsessionid=87169CD1104ADB522E4B53168DEA01DD?term=
NCT00446862&submit=Search.,%20in,%202007). The hope
is that combined angiotensin II blockade together with ERT
will be able to stabilize renal function in patients with more
severe degrees of renal involvement.
Possible future therapies
Enzyme enhancement (chaperone) therapy. Galactose, one of
the products of the enzymatic hydrolysis of GL-3, can
stabilize the protein products of some missense mutations of
the a-Gal A gene.32 Similarly, pharmacological stabilization
of the mutant protein can prevent premature degradation of
the enzyme and has been shown to substantially increase
residual a-Gal A activity.33 Because low levels of enzyme
activity (410%) appear to be protective against the
development of the disease, modest increase in chaperone-
induced enzyme activity might be beneficial in Fabry disease.
The incomplete response to ERT in some patients with Fabry
disease has been related to the inability of the enzyme to be
distributed to all cell types in the body. Chaperone molecules
may have a theoretical advantage over ERT because they are
smaller molecules and are widely distributed to all cell types,
and may cross the blood–brain barrier. Chaperone therapy is
still in early research stages and is not available for clinical use.
Infusion of structurally modified a-Gal A. Under current
treatments the infused enzyme is taken up mainly by vascular
endothelial cells, which may limit its effectiveness. Expanding
the delivery of the enzyme to all other cells by the produc-
tion of several specifically targeted glycosylated forms of
the enzyme, modifying the protein to allow for receptor-
independent uptake or using a peptide carrier delivery system
are strategies currently being proposed.34
Substrate reduction therapy. Agents used in substrate
reduction therapy (SRT) therapy block the formation of
accumulating glycosphingolipids. In the Fabry knockout
mouse model, administration of the ceramide analogue D-t-
EtDo-P4, a very potent inhibitor of glucosylceramide
synthase, caused a significant reduction in renal, hepatic
and cardiac GL-3.35 In older Fabry mice, with more severe
vascular involvement, recent studies showed the benefit of
prolonged SRT.36 These observations suggest that, in addition
to enzymatic activity, other mechanisms are involved in
the clearance of substrate in Fabry disease. Inhibitors of
GL-3 formation have the advantage of being given by mouth
and may enhance the effect of ERT. Combined therapy may
be especially relevant to the kidney since SRT appears to
cause uniform reduction of accumulated GL-3, whereas only
specific cell types appear to respond favorably to ERT.34
Gene therapy. Transduction of hematopoietic cells with
a retrovirus encoding a-Gal A to a-Gal A-deficient mice
resulted in enhanced a-Gal A as well as a decrease of GL-3
storage in all organs and tissues except the brain.37 Similarly,
long-term correction of the a-Gal A deficiency was obtained
using different adeno-associated viral vectors.38 Maintenance
of gene expression long-term as well as safety issues remain
major obstacles in translation into human studies. Additional
problems include the immune response that may lead to
clearance of and/or loss of enzyme activity.
Infusions of structurally modified a-Gal A. In patients with
Fabry disease, the bulk of infused a-Gal A is taken up by
vascular endothelial cells, thus limiting its effectiveness.
Development of several specifically target glycoforms of
the enzyme or enzyme modification by adding the TAT
protein transduction domain, thus allowing for receptor-
independent cellular uptake, has been proposed as a way to
increase delivery of a-Gal to other cells.39
CONCLUSION
There are some forms of Fabry disease in which renal involve-
ment is most outstanding and together with the cardiac
variant, represent extreme phenotypes of a single disorder. It
is of great interest for nephrologists to know the existence of
this type of patient, since the diagnosis might be difficult due
to a lack of typical signs and symptoms of Fabry disease. The
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advent of ERT has transformed Fabry disease in a potentially
treatable cause of proteinuric chronic renal disease. However,
some issues are still unresolved: a therapeutic benefit on the
cerebrovascular aspect of the disease remains to be demon-
strated. It is likely that the benefit of ERT is the same
in female as in male patients, but we do not know for sure.
This is an important issue, for females represent 12% of
Fabry patients on ERT. When should treatment be started?
In childhood? As soon as the diagnosis is made? Or should
we wait until renal function starts to decline? In the future,
better results may be achieved with the use of modified
enzyme preparations, SRT, chaperone therapy, combination
therapies, or others still in the development phase. Until then,
the available evidence strongly suggests that ERT can improve
renal function and/or slow the decline of GFR in patients
with Fabry disease and mildly to moderately reduce GFR.
However, as illustrated by the present case, progression
of disease might occur despite treatment, particularly if
ERT is initiated late in the progression of the renal disease.
The current thinking is that the sooner ERT is started, the
more likely renal disease progression will be avoided. Further
studies are needed in order to confirm these observations,
and some have already been initiated.
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